Enhanced levels of eIF2α phosphorylation have also been described in other solid tumor entities (e.g., lung cancer, PDAC, breast cancer) pointing to the possibility that modulation of the eIF2B complex might induce a vulnerability in other types of cancer (Bai et al, 2021; Ghaddar et al, 2021; Koromilas, 2015; Shin et al, 2022). This evidence concerns the gene EIF2B4 and breast cancer.